On May 2 at 17:00 CEST (11:00 EDT), Tina Vilsøll, Research Leader at the Steno Diabetes Centre, and Michael Wagner, Senior VP Chemistry & Drug Discovery at Dewpoint Therapeutics will join Martin Schain, PET Imaging Director at Antaros Medical for the webinar The Incretin Impact: A new era in metabolic disease and obesity drug development.
Together the panel of speakers will the expert speakers will cover how incretins were discovered and what we know about them, current challenges facing incretin drug development, and some of the exciting work that is ongoing in this space. They will also discuss how advanced imaging techniques like magnetic resonance imaging (MRI) and positron emission tomography (PET) can give us insights that will help us to better understand incretins, as well as provide relevant information for future drug development.
You can read more about the webinar and register here.
Title: The Incretin Impact: A new era in metabolic disease and drug development
Date and time: May 2, 17:00 CEST (11:00 EDT)
Free to register and attend